Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025.

Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed ...

Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

The resulting outcome is that you have A.I. systems that have learned what it means to solve a problem that takes quite a ...

Researchers from the University of Maryland, Lawrence Livermore, Columbia and TogetherAI have developed a training technique that triples LLM inference speed without auxiliary models or infrastructure ...

The journey towards circular high-performance composites begins with one core question: why redesign an already mature class of materials? To set the scene, we asked the consortium to describe the ...

Discover the top 4 undervalued Construction & Engineering stocks for Wednesday, February 25 based on AAII’s Stock Grades.

Markets with constrained new construction relative to demand can support both strong occupancy and predictable revenue streams.

A global team of scientists has identified an often-overlooked biological system - biofilms - as a critical factor in the ...

Lactalis debuts a ready‑to‑drink milk fortified with native type II collagen, targeting joint health, mobility and the rising ...

Q4 2025 Earnings Call February 26, 2026 8:00 AM ESTCompany ParticipantsNancy SongJinyi Guo - Co-founder, CEO & ...